Grundläggande statistik
| CIK | 896747 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to American Bio Medica Corporation
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition R |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number: 0-28666 American Bio Medica Corporation (Ex |
|
| March 21, 2023 |
Amendment No. 13 to the New Jersey facility lease, dated October 27, 2022* EXHIBIT 10.52 THIRTEENTH AMENDMENT TO MULTI-TENANT INDUSTRIAL LEASE THIS THIRTEENTH AMENDMENT TO MULTI-TENANT INDUSTRIAL LEASE (“Thirteenth Amendment”) is entered into as of this 27th day of October, 2022, by and between 603 HERON DRIVE OWNER, LLC, a Delaware limited liability company (“Landlord”) and AMERICAN BIO MEDICA CORPORATION, a New York corporation (“Tenant”). Recitals A. Landlord (as succ |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| February 17, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| January 5, 2023 |
AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 January 4, 2023 AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 January 4, 2023 VIA EDGAR (PRER14A) U. |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 21, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| December 21, 2022 |
EXHIBIT 2.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN AMERICAN BIO MEDICA CORPORATION and Healgen Scientific Limited Liability Company December 19, 2022 TABLE OF CONTENTS Article I. PURCHASE AND SALE OF ASSETS. 1 Section 1.1. Purchase and Sale of Assets 1 Section 1.2. Excluded Assets 2 Section 1.3. Assumption of Liabilities 2 Section 1.4. Retained Liabilities 2 Section 1.5. Purchase Price 3 Section |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transiti |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 29, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 28, 2022 |
DEF 14A 1 abmcdef14a.htm SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 15, 2022 |
Seventh amendment to the Certificate of Incorporation(4) EXHIBIT 3.8 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF AMERICAN BIO MEDICA CORPORATION Under Section 805 of the Business Corporation Law FIRST: The current name of the Corporation is American Bio Medica Corporation. SECOND: The Certificate of Incorporation of the Corporation was filed with the Department of State of the State of New York on April 10, 1986 under the name, Ameri |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number: 0-28666 American Bio Medica Corporation (Ex |
|
| March 31, 2022 |
OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| December 22, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| December 22, 2021 |
EXHIBIT 99.1 (UHY LLP LETTERHEAD) UHY LLP 4 Tower Place, Executive Park 7th Floor Albany, NY 12203 Main 518 449 3171 Fax 518 449 5832 Web www.uhy-use.com December 21, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We were previously principal accountants for American Bio Medica Corporation, Inc. (the ?Company?) and, under the date of April 15, |
|
| November 30, 2021 |
ABMC / American Bio Medica Corporation / Sternberg Stuart - SC 13G/A Passive Investment SC 13G/A 1 tm2134145d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) November 18, 2021 (Date of Event which Requires Filing of this Statement) C |
|
| November 18, 2021 |
ABMC REPORTS THIRD QUARTER 2021 RESULTS EXHIBIT 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS THIRD QUARTER 2021 RESULTS Kinderhook, N.Y., November 18, 2021 ? American Bio Medica Corporation (OTCQB: ABMC) today announced financial results for the three and nine months ended September 30, 2021. Chief Executive Officer Melissa A. Waterhouse stated, ?We are encourag |
|
| November 18, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transit |
|
| October 26, 2021 |
ABMC / American Bio Medica Corporation / Sternberg Stuart - SC 13G/A Passive Investment SC 13G/A 1 tm2130618d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) October 19, 2021 (Date of Event which Requires Filing of this Statement) Ch |
|
| October 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2021 |
EXHIBIT 4.28 SECURITIES PURCHASE AGREEMENT This Securities and Purchase Agreement (the ?Agreement?) is made and entered into as of the later of the dates set forth on the signature pages hereto, by and between American Bio Medica Corporation (the ?Company?) and the individual more specifically identified on the signature page of this Agreement (the ?Purchaser?). Throughout this Agreement, the Comp |
|
| August 18, 2021 |
ABMC REPORTS SECOND QUARTER 2021 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS SECOND QUARTER 2021 RESULTS Kinderhook, N.Y., August 18, 2021 ? American Bio Medica Corporation (OTCQB: ABMC) today announced financial results for the three and six months ended June 30, 2021. Chief Executive Officer Melissa A. Waterhouse stated, ?Our drugs testing mark |
|
| August 18, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Comm |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended June 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Re |
|
| July 26, 2021 |
ABMC / American Bio Medica Corporation / MORONEY JOHN J Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE13D Under the Securities Exchange Act of 1934 (Amendment No.,)* AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number John J. Moroney 118 Pegasus Dr Jupiter ,FL 33477 201-788-7271 (Name,Address and Telephone Number of Person Authorized to |
|
| June 29, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 AMERICAN BIO MEDICAL CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| June 1, 2021 |
ABMC / American Bio Medica Corporation / MORONEY JOHN J Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) James G. Dodrill II, Esq. Law Office of James G. Dodrill II, P.A. 5800 Hamilton Way Boca Raton, FL 33496 (561) 862-052 |
|
| May 20, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commiss |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q [x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| May 20, 2021 |
ABMC REPORTS FIRST QUARTER 2021 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS FIRST QUARTER 2021 RESULTS Kinderhook, N.Y., May 20, 2021 ? American Bio Medica Corporation (OTCQB: ABMC) today announced financial results for the three months ended March 31, 2021. Chief Executive Officer Melissa A. Waterhouse stated, ?As I indicated in April 2021, sal |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check One): ? Form 10-K Form ? 20-F Form ?11-K Form ? 10-Q Form ?10-D Form N-SAR ? Form N-CSR For period ended March 31, 2021 Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2021 |
Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS FOURTH QUARTER AND YEAR END 2020 RESULTS -Net Sales Increase 13.5% as Company Navigates the Covid-19 Pandemic- Kinderhook, N.Y., April 15, 2021 – American Bio Medica Corporation (OTCQB: ABMC) today announced financial results for the fourth quarter and year ended Decembe |
|
| April 15, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period - to - Commission File Number: 0-28666 American Bio Medica Corpora |
|
| March 31, 2021 |
OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2021 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 12, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-251798 PROSPECTUS 9,750,000 SHARES COMMON STOCK This prospectus relates to the sale of up to 9,750,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of our common stock to which this prospectus relates have been or may be issued by us to |
|
| January 8, 2021 |
EMAIL: [email protected] DIRECT DIAL: 212.451.2234 January 8, 2021 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Deanna Virginio, Esq. Division of Corporation Finance Re: American Bio Medica Corporation Registration Statement on Form S-1 (No. 333-251798) Filed December 29, 2020, amended January 7, 2021 Ladies and Gentlemen: On |
|
| January 7, 2021 |
As filed with the Securities and Exchange Commission on January 7, 2021 Registration No. |
|
| December 29, 2020 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on December 29, 2020 Registration No. |
|
| December 21, 2020 |
Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| December 10, 2020 |
EXHIBIT 10.45 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of December 8, 2020, by and between AMERICAN BIO MEDICA CORPORATION, a New York corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, a |
|
| December 10, 2020 |
ABMC ANNOUNCES COMMON STOCK PURCHASE AGREEMENT FOR UP TO $10M WITH LINCOLN PARK CAPITAL FUND, LLC EXHIBIT 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC ANNOUNCES COMMON STOCK PURCHASE AGREEMENT FOR UP TO $10M WITH LINCOLN PARK CAPITAL FUND, LLC Kinderhook, N.Y., December 10, 2020 – American Bio Medica Corporation (OTCQB: ABMC) today announced it has entered into a purchase agreement and registration rights agreement with Lincol |
|
| December 10, 2020 |
EXHIBIT 10.46 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 8, 2020, by and between AMERICAN BIO MEDICA CORPORATION, a New York corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein |
|
| December 10, 2020 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| November 16, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| November 16, 2020 |
Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 16, 2020 |
ABMC REPORTS THIRD QUARTER 2020 RESULTS --Announces Application to Up-List to OTCQB-- Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS THIRD QUARTER 2020 RESULTS -Announces Application to Up-List to OTCQB- Kinderhook, N.Y., November 16, 2020 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and nine months ended September 30, 2020 and announced they have app |
|
| October 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 25, 2020 |
Quarterly Report - AMENDED QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q/A Amendment No. 1 ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICA |
|
| September 15, 2020 |
ABMC REPORTS SECOND QUARTER 2020 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, EXT 107 FOR IMMEDIATE RELEASE: ABMC REPORTS SECOND QUARTER 2020 RESULTS Kinderhook, N.Y., September 15, 2020 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and six months ended June 30, 2020. Chief Executive Officer Melissa A. Waterhouse stated, “We are pleased to r |
|
| September 15, 2020 |
Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation |
|
| September 15, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) ( |
|
| August 14, 2020 |
OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 31, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| July 31, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| July 31, 2020 |
ABMC REPORTS FIRST QUARTER 2020 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS FIRST QUARTER 2020 RESULTS Kinderhook, N.Y., July 31 2020 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three months ended March 31, 2020. Chief Executive Officer Melissa A. Waterhouse stated, “Our drug testing business has bee |
|
| July 24, 2020 |
Annual Report - AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period - to - Commission File Number: 0-28666 America |
|
| June 30, 2020 |
OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period - to - Commission File Number: 0-28666 American Bio Medica Corpora |
|
| June 26, 2020 |
Amendment No. 12 to New Jersey facility lease, dated December 24, 2019(10) EXHIBIT 10.44 TWELFTH AMENDMENT TO LEASE AGREEMENT THIS TWELFTH AMENDMENT TO MULTI-TENANT INDUSTRIAL LEASE (this "Amendment") is made as of 24th day of December, 2019 by and between 603-614 HERON DRIVE LLC, a Delaware limited liability company, whose address is c/o Novaya Foxfield Industrial LLC, 265 Franklin Street, Suite 1001, Boston, Massachusetts 02110 ("Landlord"), and AMERICAN BIOMEDICA CORP |
|
| June 26, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| June 26, 2020 |
ABMC REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS EXHIBIT 99.1 FOR IMMEDIATE RELEASE: ABMC REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS Kinderhook, N.Y., June 26, 2019 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the fourth quarter and year ended December 31, 2019. Chief Executive Officer, Melissa A. Waterhouse stated, “While sales did not increase in Q4 2019 (as they did in Q3 2019), they were relativ |
|
| June 24, 2020 |
ABMC / American Bio Medica Corp. / Sternberg Stuart - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) February 19, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| May 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commiss |
|
| May 14, 2020 |
NT 10-K/A 1 abmc10kant.htm NT 10-K/A OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Expires: February 28, 2022 Estimated average burden hours per response.......2.50 FORM 12b-25 SEC FILE NUMBER 0-28666 CUSIP NUMBER NOTIFICATION OF LATE FILING 024600 (Check one): ☑ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Fo |
|
| April 27, 2020 |
ABMC / American Bio Medica Corp. / MORONEY JOHN J - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1)* Under the Securities Exchange Act of 1934 AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) James G. Dodrill II, Esq. Law Office of James G. Dodrill II, P.A. 5800 Hamilton Way Boca Raton, FL 33496 (561) 862- |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| March 30, 2020 |
ABMC / American Bio Medica Corp. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 0-28666 CUSIP NUMBER NOTIFICATION OF LATE FILING 024600 (Check one): ☑ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| March 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| March 23, 2020 |
ABMC OFFERS RAPID TEST FOR COVID-19 --Company expects distribution would materially impact sales-- Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC OFFERS RAPID TEST FOR COVID-19 -Company expects distribution would materially impact sales- Kinderhook, N.Y., March 20, 2020 – American Bio Medica Corporation (OTCPK: ABMC), a manufacturer of accurate, cost-effective immunoassay test kits, announced today that it began offering |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| February 25, 2020 |
EXHIBIT 4.27 SECURITIES PURCHASE AGREEMENT This Securities and Purchase Agreement (the “Agreement”) is made and entered into as of the later of the dates set forth on the signature pages hereto, by and between American Bio Medica Corporation (the “Company”) and the individual more specifically identified on the signature page of this Agreement (the “Purchaser”). Throughout this Agreement, the Comp |
|
| January 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2020 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2019 |
ABMC / American Bio Medica Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q [x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MED |
|
| November 14, 2019 |
ABMC REPORTS THIRD QUARTER 2019 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS THIRD QUARTER 2019 RESULTS Kinderhook, N.Y., November 14, 2019 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and nine months ended September 30, 2019. Chief Executive Officer Melissa A. Waterhouse stated, “Sales in the th |
|
| November 14, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| August 14, 2019 |
ABMC REPORTS SECOND QUARTER 2019 RESULTS Exhibit 99.1 ABMC REPORTS SECOND QUARTER 2019 RESULTS Kinderhook, N.Y., August 14, 2019 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and six months ended June 30, 2019. Chief Executive Officer Melissa A. Waterhouse stated, “We are pleased that the second quarter of 2019 was our second consecutive quarter of increased sales. While sales are down wh |
|
| August 14, 2019 |
ABMC / American Bio Medica Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q [x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA C |
|
| August 14, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) (Exact name of registrant as specified in its charter) New York 0-28666 14-17021 |
|
| June 21, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 24, 2019 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commiss |
|
| May 24, 2019 |
Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC ORAL FLUID CONSENT DECREE VACATED -Company will re-enter the employment market with oral fluid drug tests- Kinderhook, N.Y., May 20, 2019 – American Bio Medica Corporation (OTCPK: ABMC) announced today that on May 23, 2019, its Consent Decree of Permanent Injunction (Consent Dec |
|
| May 20, 2019 |
ABMC REPORTS FIRST QUARTER 2019 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, EXT 107 ABMC REPORTS FIRST QUARTER 2019 RESULTS Kinderhook, N.Y., May 20, 2019 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three months ended March 31, 2019. Chief Executive Officer Melissa A. Waterhouse stated, “New contract manufacturing sales and increased sales of |
|
| May 20, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commiss |
|
| May 20, 2019 |
ABMC / American Bio Medica Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q [x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| May 14, 2019 |
ABMC / American Bio Medica Corp. NT 10-Q PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-28666 CUSIP NUMBER 024600 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re |
|
| April 26, 2019 |
ABMC / American Bio Medica Corp. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 16, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in this charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Comm |
|
| April 16, 2019 |
ABMC REPORTS FOURTH QUARTER AND YEAR END 2018 RESULTS Exhibit 99.1 Contacts: Melissa A. Waterhouse Chief Executive Officer (800) 227-1243, Ext 107 FOR IMMEDIATE RELEASE: ABMC REPORTS FOURTH QUARTER AND YEAR END 2018 RESULTS Kinderhook, N.Y., April 16, 2019 – American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the fourth quarter and year ended December 31, 2018. Chief Executive Officer, Melissa A. Waterhouse stated, “Sa |
|
| April 16, 2019 |
ABMC / American Bio Medica Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION fWashington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period - to - Commission File Number: 0-28666 American Bio Medica Corporatio |
|
| March 29, 2019 |
ABMC / American Bio Medica Corp. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 0-28666 CUSIP NUMBER NOTIFICATION OF LATE FILING 024600 (Check one): ☑ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| March 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| December 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2018 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| December 26, 2018 |
Securities Purchase Agreement(5) EX-4.26 2 abmcex426.htm FORM OF SECURITIES PURCHASE AGREEMENT EXHIBIT 4.26 SECURITIES PURCHASE AGREEMENT This Securities and Purchase Agreement (the “Agreement”) is made and entered into as of the later of the dates set forth on the signature pages hereto, by and between American Bio Medica Corporation (the “Company”) and the individuals more specifically identified on the signature pages of this |
|
| November 13, 2018 |
ABMC / American Bio Medica Corp. PRIMARY DOCUMENT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q [x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MED |
|
| August 14, 2018 |
ABMC / American Bio Medica Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2018 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 14, 2018 |
ABMC / American Bio Medica Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q ☑ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 20, 2018 |
ABMC / American Bio Medica Corp. DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 12, 2018 |
Amendment No. 11 to New Jersey facility lease, dated November 20, 2017(10) EX-10.43 2 abmcex1043.htm AMENDMENT NO. 11 TO NEW JERSEY FACILITY LEASE, DATED NOVEMBER 20, 2017 EXHIBIT 10.43 LEASE AMENDMENT NO. 11 This Lease Amendment made and entered into this 20th day of November 2017, by and between Whitesell Enterprises, hereinafter referred to as (“Landlord”) and American Bio Medica Corporation, hereinafter referred to as (“Tenant”); WHEREAS, Landlord leased to Tenant th |
|
| April 12, 2018 |
ABMC / American Bio Medica Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period - to - Commission File Number: 0-28666 American Bio Medica Corpora |
|
| April 2, 2018 |
ABMC / American Bio Medica Corp. NT 10-K OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2018 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| January 11, 2018 |
Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2018 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporat |
|
| November 14, 2017 |
ABMC / American Bio Medica Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| August 14, 2017 |
ABMC / American Bio Medica Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2017 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| June 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2017 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| March 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ————— to ——————- Commission File Number: 0-28666 American Bio Medica C |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| November 8, 2016 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2016 |
ABMC / American Bio Medica Corp. / MORONEY JOHN J - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMERICAN BIO MEDICA CORPORATION (Name of Issuer) Common Stock, $ .01 par value (Title of Class of Securities) 024600 10 8 (CUSIP Number) James G. Dodrill II, Esq. Law Office of James G. Dodrill II, P.A. 5800 Hamilton Way Boca Raton, FL 33496 (561) 862-052 |
|
| October 4, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2016 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (C |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2016 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2016 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ??????- Commission File Number: 0-28666 American Bio Medica C |
|
| March 30, 2016 |
EXHIBIT 10.42 LEASE AMENDMENT NO. 10 This Lease Amendment made and entered into this 23rd day of December, 2015, by and between Whitesell Enterprises, hereinafter referred to as (?Landlord?) and American Bio Medica Corporation, hereinafter referred to as (?Tenant?); WHEREAS, Landlord leased to Tenant that certain premises known as Units 3, 4 and 6 at 603 Heron Drive, Logan Township, Gloucester Cou |
|
| March 3, 2016 |
ABMC / American Bio Medica Corp. / MP BIOMEDICALS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* American Bio Medica Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 024600108 (CUSIP Number) Thomas Stankovich 3 Hutton Centre Drive Suite 100 Santa Ana, CA 92707 949 833-2500 (Name, Address and Telephone Number of Person Authoriz |
|
| January 28, 2016 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2016 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| January 5, 2016 |
(Liggett, Vogt & Webb, P.A. Letterhead) EXHIBIT 99.1 (Liggett, Vogt & Webb, P.A. Letterhead) January 5, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated January 5, 2016 of American Bio Medica Corporation and are in agreement with the statements contained first sentence with regards to the dismissal of Liggett, Vogt & Webb, P.A. of the first p |
|
| January 5, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2016 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Comm |
|
| December 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2015 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| July 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2015 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| June 22, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2015 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2015 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 31, 2015 |
EXHIBIT 10.41 LEASE AMENDMENT NO. 9 This Lease Amendment made and entered into this 15th day of December, 2014, by and between Whitesell Enterprises, hereinafter referred to as (?Landlord?) and American Bio Medica Corporation, hereinafter referred to as (?Tenant?); WHEREAS, Landlord leased to Tenant that certain premises known as Units 3, 4 and 6 at 603 Heron Drive, Logan Township, Gloucester Coun |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ??????- Commission File Number: 0-28666 American Bio Medica C |
|
| March 30, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2015 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| February 25, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2015 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| February 17, 2015 |
ABMC / American Bio Medica Corp. / MP BIOMEDICALS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* American Bio Medica Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 024600108 (CUSIP Number) Thomas Stankovich 3 Hutton Centre Dr Santa Ana CA 92707 949 833-2500 (Name, Address and Telephone Number of Person Authorized to Receive |
|
| December 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2014 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of (Commission File N |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| July 31, 2014 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2014 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| June 24, 2014 |
Employment Contract between the Company and Melissa A. Waterhouse(8) EXHIBIT 10.40 June 19, 2014 Melissa A. Waterhouse PO Box 769 Philmont, New York 12565 Dear Melissa, It is our pleasure to formally offer you the position of Chief Executive Officer (“CEO”) of American Bio Medica Corporation (“ABMC” or the “Company”), reporting directly to the ABMC Board of Directors. You would also serve as the Company’s Principal Financial and Accounting Officer (“PFAO”) until su |
|
| June 24, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2014 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 14, 2014 |
ABMC / American Bio Medica Corp. / MP BIOMEDICALS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* American Bio Medica Corporation (Name of Issuer) Common (Title of Class of Securities) 024600108 (CUSIP Number) Thomas Stankovich 3 Hutton Centre Drive Suite 100 Santa Ana, CA 92707 949 833-2500 (Name, Address and Telephone Number of Person Authorized to |
|
| April 7, 2014 |
As filed with the Securities and Exchange Commission on April 7, 2014 Registration No. |
|
| April 7, 2014 |
AGREEMENT TO AMEND AND EXTEND 15% CONVERTIBLE DEBENTURE DUE AUGUST 1, 2013 EXHIBIT 4.27 AGREEMENT TO AMEND AND EXTEND 15% CONVERTIBLE DEBENTURE DUE AUGUST 1, 2013 THIS AGREEMENT (the “Agreement”) to amend and extend an existing series A 15% Convertible Debenture due August 1, 2013 (principal amount of $) (the “Debenture”) is made as of September 11, 2013 between American Bio Medica Corporation, a corporation duly organized and existing under the laws of the State of New |
|
| April 7, 2014 |
EXHIBIT 4.30 AGENT WARRANT CERTIFICATE THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OR OFFERED FOR SALE, IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES, OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT RE |
|
| April 7, 2014 |
EXHIBIT 4.29 WARRANT CERTIFICATE THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OR OFFERED FOR SALE, IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES, OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED |
|
| April 7, 2014 |
EXHIBIT 4.28 NOTE Tinton Falls, New Jersey $200,000.00 October 7, 2013 1. Obligation. For value received and intending to be legally bound, AMERICAN BIO MEDICA CORPORATION, a New York corporation (“Maker”), hereby promises to pay on or before August 1, 2014 (or earlier as determined below) (the “Due Date”) to the order of CANTONE ASSET MANAGEMENT LLC (“Payee”), the principal sum of TWO HUNDRED THO |
|
| April 7, 2014 |
EXHIBIT 4.32 No. CONFIDENTIAL PRIVATE OFFERING MEMORANDUM 15% Subordinated Convertible Debentures, Series A, due February 1, 2014 or August 1, 2014 To Replace 15% Subordinated Convertible Debentures, Series A, due August 1, 2013 American Bio Medica Corporation (“we”, “us” or the “Company”) has previously issued 10% Subordinated Convertible Debentures, Series A, due August 1, 2012 (the “Original De |
|
| April 7, 2014 |
EXHIBIT 4.31 WARRANT CERTIFICATE THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR THE SECURITIES LAWS OF ANY STATE. THEY MAY NOT BE SOLD, OR OFFERED FOR SALE, IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES, OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED |
|
| April 7, 2014 |
EXHIBIT 4.26 PLACEMENT AGENT AGREEMENT October 7, 2013 AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 RE: Placement Agent Agreement for Extension of Existing 15% Subordinated Convertible Debentures Due August 1, 2013 Dear Ms. Waterhouse: This letter confirms our agreement (the “Agreement”) that American Bio Medica Corporation, a New York corporation (“ABMC “ or the “Comp |
|
| March 31, 2014 |
EXHIBIT 10.39 LEASE AMENDMENT NO. 8 This Lease Amendment made and entered into this 4th day of December 2013, by and between Whitesell Enterprises, hereinafter referred to as (“landlord”) and American Bio Medica Corporation, hereinafter referred to as (“Tenant”); WHEREAS, Landlord leased to Tenant that certain premises known as Units 3,4 and 6, 603 Heron drive, Bridgeport, New Jersey, consisting o |
|
| March 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number: 0-28666 American Bio Medica Corporation (Ex |
|
| January 27, 2014 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2014 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| November 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 0-28666 (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For period ended September 30, 2013 ¨ Transition Report on Form 10-KSB ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report o |
|
| November 12, 2013 |
EXHIBIT 10.38 November 6, 2013 Melissa A. Waterhouse PO Box 769 Philmont, New York 12565 Dear Melissa, It is our pleasure to formally offer you the position of interim Chief Executive Officer/Chief Financial Officer of American Bio Medica Corporation (“ABMC” or the “Company”), reporting directly to the ABMC Board of Directors. This agreement supersedes all other agreements whether written or verba |
|
| November 12, 2013 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of (Commission File Nu |
|
| November 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| August 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2013 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 25, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of (Commission File Number |
|
| May 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2013 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 28, 2013 |
EXHIBIT 10.37 LEASE AMENDMENT NO. 7 This Lease Amendment made and entered into this 12th day of December 2012, by and between Whitesell Enterprises, hereinafter referred to as (?Landlord?) and American Bio Medica Corporation, hereinafter referred to as (?Tenant?); WHEREAS, Landlord leased to Tenant that certain premises known as Units 3, 4 and 6, 603 Heron Drive, Bridgeport, New Jersey, consisting |
|
| March 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ?????? Commission File Number: 0-28666 American Bio Medica Co |
|
| March 15, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| February 8, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| February 8, 2013 |
Exhibit 4.24 Monarch Capital Group, LLC CONFIDENTIAL January 23, 2013 Mr. Stan Cipkowski Chief Executive Officer American Bio Medica Corporation 122 Smith Road Kinderhook, NY 12106 Re: Engagement of Monarch Capital Group, LLC Dear Mr. Cipkowski: Monarch Capital Group, LLC (“we" or "MCG”) would be pleased to act as non-exclusive financial advisor for American Bio Medica Corporation, (“you" or the " |
|
| February 7, 2013 |
Entry into a Material Definitive Agreement - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of |
|
| January 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2013 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| January 22, 2013 |
Exhibit 99.1 ABMC COMPLETES DEBT REFINANCING -New Secured Revolving Credit Facility will provide the Company with up to $3Million- Kinderhook, N.Y., January 22, 2013 - American Bio Medica Corporation (ABMC.PK) today announced that they have entered into an agreement with Imperium Commercial Finance Master Fund LP (“Imperium”) that provides the Company with a secured revolving line of credit of up |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| October 25, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2012 |
EXHIBIT 99.1 (Sherb & Co., LLP Letterhead) October 24, 2012 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated October 24, 2012 of American Bio Medica Corporation and are in agreement with the statements contained first sentence with regards to the dismissal of Sherb & Co., LLP, of the first paragraph, the sec |
|
| September 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q/A (Amendment No. 1) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2012 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERI |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2012 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| August 6, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| August 6, 2012 |
EXHIBIT 4.23 August 1, 2012 AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 Gentlemen: This letter agreement (the "Agreement") confirms the terms and conditions of the non-exclusive engagement of Cantone Asset Management LLC ("CAM"), by American Bio Medica Corporation (together with its legal successors, the "Company"), to render financial advisory services and advice as |
|
| August 6, 2012 |
AGREEMENT TO AMEND SECURITIES PURCHASE AGREEMENT AND 10% CONVERTIBLE DEBENTURE DUE AUGUST 1, 2012 EXHIBIT 4.22 AGREEMENT TO AMEND SECURITIES PURCHASE AGREEMENT AND 10% CONVERTIBLE DEBENTURE DUE AUGUST 1, 2012 THIS AGREEMENT (the “Agreement”) to amend the Securities Purchase Agreement dated (the “Purchase Agreement”) and that certain 10% Convertible Debenture due August 1, 2012 is made as of July 31, 2012 between American Bio Medica Corporation, a corporation duly organized and existing under t |
|
| July 31, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of (Commission File Numbe |
|
| July 31, 2012 |
EXHIBIT 4.19 PLACEMENT AGENT AGREEMENT July 25, 2012 AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 RE: Placement Agent Agreement for Extension of Existing 10% Subordinated Convertible Debentures Dear Mr. Cipkowski: This letter confirms our agreement that American Bio Medica Corporation, a New York corporation (“ABMC ” or the "Company”) has engaged Cantone Research, Inc. |
|
| July 31, 2012 |
EX-4.20 3 v319979ex4-20.htm EXHIBIT 4.20 EXHIBIT 4.20 BRIDGE LOAN AGREEMENT July 30, 2012 AMERICAN BIO MEDICA CORPORATION 122 Smith Road Kinderhook, New York 12106 RE: Bridge Loan Agreement Dear Mr. Cipkowski: In reference to the pending offering for the extension of $750,000 in existing debt (the “Existing Debt”) of American Bio Medica Corporation, a New York corporation (“ABMC ” or the "Company” |
|
| July 31, 2012 |
EX-4.21 4 v319979ex4-21.htm EXHIBIT 4.21 EXHIBIT 4.21 NOTE Tinton Falls, New Jersey $150,000.00 July 31, 2012 1. Obligation. For value received and intending to be legally bound, AMERICAN BIO MEDICA CORPORATION, a New York corporation ("Maker"), hereby promises to pay on or before July 31, 2013 (or earlier as determined below) (the “Due Date”) to the order of CANTONE ASSET MANAGEMENT LLC ("Payee") |
|
| July 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| July 10, 2012 |
EXHIBIT 99.1 FOR IMMEDIATE RELEASE: ABMC ANNOUNCES SIGNING OF CONSENT DECREE RELATED TO ITS ORALSTAT® PRODUCT — Company Allowed to Continue to Sell OralStat in Workplace Settings With Conditions While Obtaining 510(k) Clearance— KINDERHOOK, NY, July 10, 2012 – American Bio Medica Corporation (ABMC.PK) announced today that the Company and its officers, Stan Cipkowski and Melissa Waterhouse, have en |
|
| June 18, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2012 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 25, 2012 |
Exhibit 10.26 April 20, 2012 Melissa A. Waterhouse PO Box 769 Philmont, New York 12565 Dear Melissa, It is our pleasure to formally offer you the position of Executive Vice President and Chief Compliance Officer of American Bio Medica Corporation (“ABMC” or the “Company”), reporting directly to the ABMC Chief Executive Officer. This agreement supersedes all other agreements whether written or verb |
|
| April 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| April 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ?????? Commission File Number: 0-28666 American Bio Medica Co |
|
| April 16, 2012 |
EXHIBIT 10.35 LEASE AMENDMENT NO. 6 This Lease Amendment made and entered into this 1st day of December 2011, by and between Whitesell Enterprises, hereinafter referred to as (?Landlord?) and American Bio Medica Corporation, hereinafter referred to as (?Tenant?); WHEREAS, Landlord leased to Tenant that certain premises known as Units 3, 4 and 6, 603 Heron Drive, Bridgeport, New Jersey, consisting |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number 0-28666 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended December 31, 2011 o Transition Report on Form 10-KSB o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on |
|
| February 14, 2012 |
ABMC / American Bio Medica Corp. / MP BIOMEDICALS LLC - SC 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* American Bio Medica Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 024600108 (CUSIP Number) 11/28/2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 13, 2012 |
Exhibit 99.1 {UHY, LLP Letterhead} January 11, 2012 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 RE: American Bio Medica Corporation We have read the statements made by American Bio Medica Corporation under Item 4.01 of the Form 8-K report filed on January 3, 2012 regarding the recent change of auditors. We agree with such statements made regarding our firm. /s/ UHY LLP |
|
| January 13, 2012 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A-1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2012 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) |
|
| January 3, 2012 |
Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2011 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2011 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| August 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2011 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| June 15, 2011 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2011 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2011 ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 28, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2011 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commi |
|
| March 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ?????? Commission File Number: 0-28666 American Bio Medica Co |
|
| December 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2010 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA |
|
| October 21, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Com |
|
| September 3, 2010 |
EXHIBIT 10.33.1 August 18, 2010 Stefan Parker 5 Wood Duck Place Waterford, NY 12188 Dear Stefan, On August 18, 2010, the Compensation Committee of the American Bio Medica Corporation (?ABMC? or the ?Company?) Board of Directors recommended that the base salary outlined in your August 22, 2007 employment letter (the ?Employment Letter?) be increased from $120,000 on an annualized basis, to $135,000 |
|
| September 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction o |
|
| August 20, 2010 |
EX-10.33 2 v194626ex10-33.htm EX-10.33 EXHIBIT 10.33 August 18, 2010 Stefan Parker 5 Wood Duck Place Waterford, NY 12188 Dear Stefan, On August 18, 2010, the Compensation Committee of the American Bio Medica Corporation (“ABMC” or the “Company”) Board of Directors recommended that the base salary outlined in your August 22, 2007 employment letter (the “Employment Letter”) be increased from $120,00 |
|
| August 20, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Comm |
|
| August 20, 2010 |
EX-10.34 3 v194626ex10-34.htm EX-10.34 EXHIBIT 10.34 August 18, 2010 Melissa A. Waterhouse PO Box 769 Philmont, New York 12565 American Bio Medica Corporation (the "Company") considers it essential to the best interests of its shareholders to attract top executives and to foster the continuous employment of key management personnel. In this connection, the Board of Directors of the Company (the "B |
|
| August 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2010 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPO |
|
| August 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| June 17, 2010 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2010 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Commis |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2010 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORP |
|
| April 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 30, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ??????- Commission File Number: 0-28666 American Bio Medica C |
|
| January 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ????? to ?????? Commission File Number: 0-28666 Am |
|
| December 31, 2009 |
December 31, 2009 VIA EDGAR Jim B. Rosenberg, Senior Assistant Chief Accountant Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: American Bio Medica Corporation Form 10-K for Fiscal Year Ended December 31, 2008 File No. 000-28666 Dear Mr. Rosenberg: On behalf of American Bio Medica Corporation (the ?Company?), this lette |
|
| December 18, 2009 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2009 AMERICAN BIO MEDICA CORPORATION (Exact name of registrant as specified in its charter) New York 0-28666 14-1702188 (State or other jurisdiction of incorporation) (Co |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q x Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2009 ? Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-28666 AMERICAN BIO MEDICA CORPORATION |
|
| November 13, 2009 |
EXHIBIT 10.32 July 1, 2009 Stan Cipkowski 2054 River Road Melrose, NY 12121 Dear Stan, It is our pleasure to formally continue your position of Chief Executive Officer of American Bio Medica Corporation (?ABMC? or the ?Company?), reporting directly to the ABMC Board of Directors. This agreement supersedes all other agreements whether written or verbal and may not be amended except by a writing sig |
|
| August 28, 2009 |
ABMC RECEIVES NASDAQ DELISTING NOTICE EXHIBIT 99.1 FOR IMMEDIATE RELEASE: ABMC RECEIVES NASDAQ DELISTING NOTICE KINDERHOOK, NY, August 28, 2009 ? American Bio Medica Corporation (NASDAQ:ABMC) announced today that, on August 25, 2009, it received a delisting notice from the NASDAQ Stock Market, for failure to regain compliance with the minimum bid price requirement pursuant to Listing Rule 5550(a)(2). The Company can request a hearing |
